Amadeus APEX Technology Fund

Amadeus Capital Partners is a deep tech venture capital firm that invests from seed to growth stages. Since 1997, they have backed over 200 companies and raised over $1.3 billion for investment. Their investment strategy focuses on solving hard problems in large markets within three core technology areas: Intelligence (AI, advanced computing, and quantum), Human (health, medicine, and wellness), and Planet (sustainability, energy, novel materials, and space utilization). The firm aims to create value by supporting trailblazing companies in these sectors. The firm emphasizes a long-term perspective, as demonstrated by their investments in companies like OrganOx, where they saw a 14-year journey from initial investment by The Royal Society to its acquisition by Terumo for $1.5 billion. This commitment to nurturing companies over the long term suggests a patient capital approach. The firm actively seeks opportunities in European Deep Tech through a partnership with APEX Ventures, highlighted by the Amadeus APEX Technology Fund, which invests in areas like space technology. Amadeus Capital Partners has a track record of successful exits, including the acquisitions of OrganOx, Ravelin, and Cryptosense. These exits validate their investment thesis and demonstrate their ability to identify and support companies with strong growth potential. Their investment in Sitehop, a leader in post-quantum cryptography, underscores their focus on emerging technologies and their willingness to invest in early-stage ventures with significant market opportunities. By focusing on deep tech areas aligned with Intelligence, Human, and Planet, Amadeus Capital Partners positions itself to capitalize on the transformative potential of these technologies. The firm's experience, extensive network, and proven track record make it a valuable partner for entrepreneurs seeking to build innovative and impactful companies.